Clinical Report: Impact of Bariatric Surgery on COVID-19 Vaccine Serological Response

Overview

This study evaluated the serological response to COVID-19 vaccination in patients with obesity before and after bariatric surgery compared to healthy controls. Results indicate that obesity negatively affects antibody levels post-vaccination, while bariatric surgery may improve serological responses. Adverse events were also monitored to assess vaccine safety in this population.

Background

COVID-19 vaccines have been widely administered globally since late 2020, with various vaccines available in Egypt including AstraZeneca, Sinopharm, Pfizer, Moderna, and Johnson & Johnson. Patients with obesity are at higher risk for severe COVID-19 outcomes and may have diminished vaccine-induced antibody responses. Bariatric surgery induces significant weight loss and body composition changes, which could potentially reverse the negative impact of obesity on vaccine efficacy. Measuring anti-spike protein IgG antibodies remains the standard for assessing vaccine-induced immunity.

Data Highlights

Serological response was categorized by antibody levels: negative (<1 U/mL), low positive (1–5 U/mL), medium positive (>5–10 U/mL), and strong positive (>10 U/mL) with a maximum cutoff of 250 U/mL.

Key Findings

• Obesity is associated with a lower serological response to COVID-19 vaccination compared to healthy individuals.
• Bariatric surgery patients showed improved serological responses compared to obese patients awaiting surgery.
• The study included 276 participants divided into healthy controls, obese pre-surgery, and post-bariatric surgery groups.
• Serological responses were measured quantitatively using the Elecsys® Anti-SARS-CoV-2 S assay targeting spike protein RBD antibodies.
• Adverse events following vaccination were monitored and graded according to FDA guidance, though specific safety data were not detailed in the excerpt.

Clinical Implications

Clinicians should consider that obesity may impair the immune response to COVID-19 vaccines, potentially necessitating tailored vaccination strategies or booster doses in this population. Bariatric surgery may enhance vaccine-induced immunity by reversing obesity-related immunological deficits. Monitoring antibody levels post-vaccination in bariatric patients could inform personalized patient management and optimize protection against COVID-19.

Conclusion

Bariatric surgery appears to mitigate the negative impact of obesity on COVID-19 vaccine serological responses, supporting its role in improving immune protection in this high-risk population. Further studies are warranted to confirm these findings and guide vaccination protocols.

References

1. WHO 2020 -- COVID-19 Pandemic Declaration
2. FDA 2020 -- Emergency Use Authorization for COVID-19 Vaccines
3. Egyptian Ministry of Health 2021 -- COVID-19 Vaccination Campaign
4. Roche Diagnostics 2021 -- Elecsys Anti-SARS-CoV-2 S Assay
5. Hmisc R Package -- Statistical Power Analysis